A multiscale view of therapeutic protein aggregation: A colloid science perspective

Biotechnology Journal

Volumn 10, Issue 3, 2015, Pages 367-378

  Nicoud, Lucrèce ^a   Owczarz, Marta ^a   Arosio, Paolo ^b   Morbidelli, Massimo ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Fractal scaling; Molecular interaction potentials; Occupied volume fraction; Population balance equations modeling; Protein aggregation mechanism

Indexed keywords

AGGLOMERATION; AGGREGATES; COLLOIDS; FRACTALS; MOLECULAR INTERACTIONS; MOLECULAR STRUCTURE; MORPHOLOGY; STABILITY; THERMODYNAMICS; VOLUME FRACTION;

AGGREGATE VOLUME FRACTIONS; FRACTAL SCALING; FUNDAMENTAL MECHANISMS; INTERACTION POTENTIALS; KINETICS AND THERMODYNAMICS; MACROSCOPIC PROPERTIES; POPULATION BALANCE EQUATION; PROTEIN AGGREGATION;

PROTEINS;

PROTEIN; SOLVENT; PROTEIN AGGREGATE;

ATOMIC FORCE MICROSCOPY; COLLOID; CONFORMATIONAL TRANSITION; ELECTROPHORETIC MOBILITY; ENVIRONMENTAL STRESS; FIELD FLOW FRACTIONATION; GEL PERMEATION CHROMATOGRAPHY; HYDRODYNAMICS; HYDROGEN BOND; IONIC STRENGTH; LIGHT SCATTERING; MOLECULAR INTERACTION; MORPHOLOGY; PH; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; SEDIMENTATION RATE; SIMULATION; SOLVENT EFFECT; STATIC ELECTRICITY; THEORETICAL MODEL; THERMODYNAMICS; TRANSMISSION ELECTRON MICROSCOPY; ULTRACENTRIFUGATION; VISCOSITY; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; FRACTAL ANALYSIS; HUMAN;

COMPUTER SIMULATION; FRACTALS; HUMANS; MODELS, MOLECULAR; PROTEIN AGGREGATES; PROTEIN STABILITY; PROTEINS; THERMODYNAMICS;

EID: 84924491222     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201400858     Document Type: Review

References (104)

1. nd pharmacological classification. Nat. Rev. Drug Discov. 2008, 7, 21-39.
2. Hawe, A., Wiggenhorn, M., van de Weert, M., Garbe, J. H. O. et al., Forced degradation of therapeutic proteins. J. Pharm. Sci. 2012, 101, 895-913.
3. Vázquez-Rey, M., Lang, D. A., Aggregates in monoclonal antibody manufacturing processes. Biotechnol. Bioeng. 2011, 108, 1494-1508.
4. Filipe, V., Hawe, A., Schellekens, H., Jiskoot, W., Aggregation and Immunogenicity of Therapeutic Proteins, Aggregation of Therapeutic Proteins, John Wiley & Sons, Inc. 2010, pp. 403-433.
5. Rouet, R., Lowe, D., Christ, D., Stability engineering of the human antibody repertoire. FEBS Lett. 2014, 588, 269-277.
6. Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., Trout, B. L., Design of therapeutic proteins with enhanced stability. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 11937-11942.
7. Frokjaer, S., Otzen, D. E., Protein drug stability: A formulation challenge. Nat. Rev. Drug Discov. 2005, 4, 298-306.
8. Kamerzell, T. J., Esfandiary, R., Joshi, S. B., Middaugh, C. R., Volkin, D. B., Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Adv. Drug Deliv. Rev. 2011, 63, 1118-1159.
9. Chi, E. Y., Krishnan, S., Randolph, T. W., Carpenter, J. F., Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm. Res. 2003, 20, 1325-1336.
10. Ohtake, S., Kita, Y., Arakawa, T., Interactions of formulation excipients with proteins in solution and in the dried state. Adv. Drug Deliv. Rev. 2011, 63, 1053-1073.
11. Wang, W., Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 2005, 289, 1-30.
12. Uchiyama, S., Liquid formulation for antibody drugs. BBA-Proteins Proteom. 2014, 1844, 2041-2052.
13. Roberts, C. J., Das, T. K., Sahin, E., Predicting solution aggregation rates for therapeutic proteins: approaches and challenges. Int. J. Pharm. 2011, 418, 318-333.
14. Weiss, W. F. t., Young, T. M., Roberts, C. J., Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. J. Pharm. Sci. 2009, 98, 1246-1277.
15. Hamrang, Z., Rattray, N. J. W., Pluen, A., Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation. Trends Biotechnol. 2013, 31, 448-458.
16. Adamcik, J., Mezzenga, R., Proteins fibrils from a polymer physics perspective. Macromolecules 2011, 45, 1137-1150.
17. Pappu, R. V., Wang, X., Vitalis, A., Crick, S. L., A polymer physics perspective on driving forces and mechanisms for protein aggregation. Arch. Biochem. Biophys. 2008, 469, 132-141.
18. Russel, W. B., Saville, D. A., Schowalter, W. R., Colloidal Dispersions, Cambridge University Press 1992.
19. Everett, D. H., Basic Principles of Colloid Science, Royal Society of Chemistry, London 1988.
20. Sanchez-Ruiz, J. M., Protein kinetic stability. Biophys. Chem. 2010, 148, 1-15.
21. Chiti, F., Stefani, M., Taddei, N., Ramponi, G., Dobson, C. M., Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 2003, 424, 805-808.
22. van Gunsteren, W. F., Bakowies, D., Baron, R., Chandrasekhar, I. et al., Biomolecular Modeling: Goals, Problems, Perspectives. Angew. Chem. Int. Edit. 2006, 45, 4064-4092.
23. Agrawal, N. J., Kumar, S., Wang, X. L., Helk, B. et al., Aggregation in Protein-Based Biotherapeutics: Computational Studies and Tools to Identify Aggregation-Prone Regions. J. Pharm. Sci. 2011, 100, 5081-5095.
24. Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., Trout, B. L., Prediction of aggregation prone regions of therapeutic proteins. J. Phys. Chem. B 2010, 114, 6614-6624.
25. Sormanni, P., Aprile, F. A., Vendruscolo, M., The CamSol method of rational design of protein mutants with enhanced solubility. J. Mol. Biol. 2015, 427, 478-490.
26. Jha, P. K., Larson, R. G., Assessing the Efficiency of Polymeric Excipients by Atomistic Molecular Dynamics Simulations. Mol. Pharmaceutics 2014, 11, 1676-1686.
27. Shukla, D., Schneider, C. P., Trout, B. L., Molecular level insight into intra-solvent interaction effects on protein stability and aggregation. Adv. Drug Deliv. Rev. 2011, 63, 1074-1085.
28. Baynes, B. M., Trout, B. L., Rational design of solution additives for the prevention of protein aggregation. Biophys. J. 2004, 87, 1631-1639.
29. Blanco, M. A., Sahin, E., Robinson, A. S., Roberts, C. J., coarse-grained model for colloidal protein interactions, B22, and protein cluster formation. J. Phys. Chem. B 2013, 117, 16013-16028.
30. Riniker, S., Allison, J. R., van Gunsteren, W. F., On developing coarse-grained models for biomolecular simulation: a review. Phys. Chem. Chem. Phys. 2012, 14, 12423-12430.
31. Ruff, K. M., Khan, S. J., Pappu, R. V., A coarse-grained model for polyglutamine aggregation modulated by amphipathic flanking sequences. Biophys. J. 2014, 107, 1226-1235.
32. Cellmer, T., Bratko, D., Prausnitz, J. M., Blanch, H. W., Protein aggregation in silico. Trends Biotechnol. 2007, 25, 254-261.
33. Neal, B. L., Asthagiri, D., Lenhoff, A. M., molecular origins of osmotic second virial coefficients of proteins. Biophys. J. 1998, 75, 2469-2477.
34. Lehermayr, C., Mahler, H.-C., Mäder, K., Fischer, S., Assessment of net charge and protein-protein interactions of different monoclonal antibodies. J. Pharm. Sci. 2011, 100, 2551-2562.
35. Saito, S., Hasegawa, J., Kobayashi, N., Tomitsuka, T. et al., Effects of ionic strength and sugars on the aggregation propensity of monoclonal antibodies: influence of colloidal and conformational stabilities. Pharm. Res. 2013, 30, 1263-1280.
36. Arzensek, D., Kuzman, D., Podgornik, R., Colloidal interactions between monoclonal antibodies in aqueous solutions. J. Colloid Interface Sci. 2012, 384, 207-216.
37. Hiemenz, P. C., Principles of Colloid and Surface Chemistry, Dekker, USA 1986.
38. Olsen, S. N., Andersen, K. B., Randolph, T. W., Carpenter, J. F., Westh, P., Role of electrostatic repulsion on colloidal stability of Bacillus halmapalus alpha-amylase. Biochim. Biophys. Acta 2009, 1794, 1058-1065.
39. De Young, L. R., Fink, A. L., Dill, K. A., Aggregation of globular proteins. Acc. Chem. Res. 1993, 26, 614-620.
40. Arosio, P., Jaquet, B., Wu, H., Morbidelli, M., On the role of salt type and concentration on the stability behavior of a monoclonal antibody solution. Biophys. Chem. 2012, 168-169, 19-27.
41. Israelachvili, J. N., Intermolecular and Surface Forces: Revised Third Edition, Academic Press 2011.
42. Brummitt, R. K., Nesta, D. P., Chang, L., Chase, S. F. et al., Nonnative aggregation of an IgG1 antibody in acidic conditions: part 1. Unfolding, colloidal interactions, and formation of high-molecular-weight aggregates. J. Pharm. Sci. 2011, 100, 2087-2103.
43. Grant, M. L., Nonuniform Charge Effects in Protein-Protein Interactions. J. Phys. Chem. B 2001, 105, 2858-2863.
44. Valente, J. J., Payne, R. W., Manning, M. C., Wilson, W. W., Henry, C. S., Colloidal behavior of proteins: effects of the second virial coefficient on solubility, crystallization and aggregation of proteins in aqueous solution. Curr. Pharm. Biotechnol. 2005, 6, 427-436.
45. Scherer, T. M., Liu, J., Shire, S. J., Minton, A. P., Intermolecular Interactions of IgG1 Monoclonal Antibodies at High Concentrations Characterized by Light Scattering. J. Phys. Chem. B 2010, 114, 12948-12957.
46. Bajaj, H., Sharma, V. K., Kalonia, D. S., A high-throughput method for detection of protein self-association and second virial coefficient using size-exclusion chromatography through simultaneous measurement of concentration and scattered light intensity. Pharm. Res. 2007, 24, 2071-2083.
47. Saluja, A., Fesinmeyer, R. M., Hogan, S., Brems, D. N., Gokarn, Y. R., Diffusion and sedimentation interaction parameters for measuring the second virial coefficient and their utility as predictors of protein aggregation. Biophys. J. 2010, 99, 2657-2665.
48. Tessier, P. M., Lenhoff, A. M., Sandler, S. I., Rapid measurement of protein osmotic second virial coefficients by self-interaction chromatography. Biophys. J. 2002, 82, 1620-1631.
49. Sahin, E., Grillo, A. O., Perkins, M. D., Roberts, C. J., Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. J. Pharm. Sci. 2010, 99, 4830-4848.
50. Bajaj, H., Sharma, V. K., Badkar, A., Zeng, D. et al., Protein structural conformation and not second virial coefficient relates to long-term irreversible aggregation of a monoclonal antibody and ovalbumin in solution. Pharm. Res. 2006, 23, 1382-1394.
51. Chi, E. Y., Krishnan, S., Kendrick, B. S., Chang, B. S. et al., Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci. 2003, 12, 903-913.
52. Johnson, C. M., Differential scanning calorimetry as a tool for protein folding and stability. Arch. Biochem. Biophys. 2013, 531, 100-109.
53. Garidel, P., Hegyi, M., Bassarab, S., Weichel, M., A rapid, sensitive and economical assessment of monoclonal antibody conformational stability by intrinsic tryptophan fluorescence spectroscopy. Biotechnol. J. 2008, 3, 1201-1211.
54. Hawe, A., Sutter, M., Jiskoot, W., Extrinsic fluorescent dyes as tools for protein characterization. Pharm. Res. 2008, 25, 1487-1499.
55. Kelly, S. M., Price, N. C., The use of circular dichroism in the investigation of protein structure and function. Curr. Protein Pept. Sci. 2000, 1, 349-384.
56. Andrews, J. M., Roberts, C. J., A Lumry-Eyring nucleated polymerization model of protein aggregation kinetics: 1. Aggregation with pre-equilibrated unfolding. J. Phys. Chem. B 2007, 111, 7897-7913.
57. Li, Y., Roberts, C. J., Lumry-Eyring nucleated-polymerization model of protein aggregation kinetics. 2. Competing growth via condensation and chain polymerization. J. Phys. Chem. B 2009, 113, 7020-7032.
58. Roberts, C. J., Kinetics of irreversible protein aggregation: Analysis of extended Lumry-Eyring models and implications for predicting protein shelf-life. J. Phys. Chem. B 2003, 107, 1194-1207.
59. Roberts, C. J., Non-native protein aggregation kinetics. Biotechnol. Bioeng. 2007, 98, 927-938.
60. Gillam, J. E., MacPhee, C. E., modelling amyloid fibril formation kinetics: Mechanisms of nucleation and growth. J. Phys. Condens. Matter 2013, 25, 373101.
61. Knowles, T. P., Waudby, C. A., Devlin, G. L., Cohen, S. I. et al., An analytical solution to the kinetics of breakable filament assembly. Science 2009, 326, 1533-1537.
62. Amin, S., Barnett, G. V., Pathak, J. A., Roberts, C. J., Sarangapani, P. S., Protein aggregation, particle formation, characterization & rheology. Curr. Opin. Colloid Interface Sci. 2014, 19, 438-449.
63. Nicoud, L., Arosio, P., Sozo, M., Yates, A. et al., Kinetic analysis of the multistep aggregation mechanism of monoclonal antibodies. J. Phys. Chem. B 2014, 118, 10595-10606.
64. Nicoud, L., Sozo, M., Arosio, P., Yates, A. et al., Role of cosolutes in the aggregation kinetics of monoclonal antibodies. J. Phys. Chem. B 2014, 118, 11921-11930.
65. Carpenter, J. F., Randolph, T. W., Jiskoot, W., Crommelin, D. J. et al., Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products. J. Pharm. Sci. 2010, 99, 2200-2208.
66. Sharma, V. K., Kalonia, D. S., Experimental detection and characterization of protein aggregates, Aggregation of Therapeutic Proteins, John Wiley & Sons, Inc. 2010, pp. 205-256.
67. Brummitt, R. K., Nesta, D. P., Chang, L., Kroetsch, A. M., Roberts, C. J., Nonnative aggregation of an IgG1 antibody in acidic conditions, part 2: nucleation and growth kinetics with competing growth mechanisms. J. Pharm. Sci. 2011, 100, 2104-2119.
68. Telikepalli, S. N., Kumru, O. S., Kalonia, C., Esfandiary, R. et al., Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions. J. Pharm. Sci. 2014, 103, 796-809.
69. Sorensen, C. M., Roberts, G. C., The prefactor of fractal aggregates. J. Colloid Interface Sci. 1997, 186, 447-452.
70. Meakin, P., The growth of fractal aggregates, in: Pynn, R., Riste, T. (Eds.), Time-Dependent Effects in Disordered Materials, Springer US 1987, pp. 45-70.
71. González, A. E., Martiìnez-López, F., Moncho-Jordá, A., Hidalgo-Álvarez, R., Concentration effects on two- and three-dimensional colloidal aggregation. Physica A 2002, 314, 235-245.
72. Harshe, Y. M., Ehrl, L., Lattuada, M., Hydrodynamic properties of rigid fractal aggregates of arbitrary morphology. J. Colloid Interface Sci. 2010, 352, 87-98.
73. Arosio, P., Rima, S., Lattuada, M., Morbidelli, M., Population balance modeling of antibodies aggregation kinetics. J. Phys. Chem. B 2012, 116, 7066-7075.
74. Grancic, P., Illeova, V., Polakovic, M., Sefcik, J., Thermally induced inactivation and aggregation of urease: Experiments and population balance modelling. Chem. Eng. Sci. 2012, 70, 14-21.
75. Ikeda, S., Foegeding, E. A., Hagiwara, T., Rheological study on the fractal nature of the protein gel structure. Langmuir 1999, 15, 8584-8589.
76. Feder, J., Jossang, T., Rosenqvist, E., Scaling behavior and cluster fractal dimension determined by light-scattering from aggregating proteins. Phys. Rev. Lett. 1984, 53, 1403-1406.
77. Mezzenga, R., Fischer, P., The self-assembly, aggregation and phase transitions of food protein systems in one, two and three dimensions. Rep. Prog. Phys. 2013, 76, 046601.
78. Arosio, P., Barolo, G., Muller-Spath, T., Wu, H., Morbidelli, M., Aggregation stability of a monoclonal antibody during downstream processing. Pharm. Res. 2011, 28, 1884-1894.
79. Arosio, P., Rima, S., Morbidelli, M., Aggregation Mechanism of an IgG2 and two IgG1 Monoclonal Antibodies at low pH: From Oligomers to Larger Aggregates. Pharm. Res. 2013, 30, 641-654.
80. Lattuada, M., Sandkuhler, P., Wu, H., Sefcik, J., Morbidelli, M., Aggregation kinetics of polymer colloids in reaction limited regime: experiments and simulations. Adv. Colloid Interface Sci. 2003, 103, 33-56.
81. Ramkrishna, D., Population Balances: Theory and Applications to Particulate Systems in Engineering, Academic Press 2000.
82. Von Smoluchowski, M., Versuch einer mathematischen Theorie der Koagulationskinetik kolloidaler Lösungen. Z. Phys. Chem. 1917, 92, 129-168.
83. Lilyestrom, W. G., Yadav, S., Shire, S. J., Scherer, T. M., Monoclonal Antibody Self-Association, Cluster Formation, and Rheology at High Concentrations. J. Phys. Chem. B 2013, 117, 6373-6384.
84. Jezek, J., Rides, M., Derham, B., Moore, J. et al., Viscosity of concentrated therapeutic protein compositions. Adv. Drug Deliv. Rev. 2011, 63, 1107-1117.
85. Salinas, B. A., Sathish, H. A., Bishop, S. M., Harn, N. et al., Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation. J. Pharm. Sci. 2010, 99, 82-93.
86. Shire, S. J., Shahrokh, Z., Liu, J., Challenges in the development of high protein concentration formulations. J. Pharm. Sci. 2004, 93, 1390-1402.
87. Genovese, D. B., Shear rheology of hard-sphere, dispersed, and aggregated suspensions, and filler-matrix composites. Adv. Colloid Interface Sci. 2012, 171-172, 1-16.
88. Szymanski, J., Patkowski, A., Wilk, A., Garstecki, P., Holyst, R., Diffusion and Viscosity in a Crowded Environment: from Nano- to Macroscale. J. Phys. Chem. B 2006, 110, 25593-25597.
89. Beaven, G. H., Gratzer, W. B., Davies, H. G., Formation and structure of gels and fibrils from glucagon. Eur. J. Biochem. 1969, 11, 37-42.
90. Yang, Y.-l., Kaufman, L. J., Rheology and Confocal Reflectance Microscopy as Probes of Mechanical Properties and Structure during Collagen and Collagen/Hyaluronan Self-Assembly. Biophys. J. 2009, 96, 1566-1585.
91. Esue, O., Xie, A. X., Kamerzell, T. J., Patapoff, T. W., Thermodynamic and structural characterization of an antibody gel. MAbs 2013, 5, 323-334.
92. Owczarz, M., Bolisetty, S., Mezzenga, R., Arosio, P., Sol-gel transition of charged fibrils composed of a model amphiphilic peptide. J. Colloid Interface Sci. 2015, 437, 244-251.
93. Sandkühler, P., Sefcik, J., Morbidelli, M., Kinetics of gel formation in dilute dispersions with strong attractive particle interactions. Adv. Colloid Interface Sci. 2004, 108-109, 133-143.
94. Pouzot, M., Nicolai, T., Durand, D., Benyahia, L., Structure factor and elasticity of a heat-set globular protein gel. Macromolecules 2004, 37, 614-620.
95. Philipse, A. P., Wierenga, A. M., On the density and structure formation in gels and clusters of colloidal rods and fibers. Langmuir 1998, 14, 49-54.
96. Hagiwara, T., Kumagai, H., Nakamura, K., Fractal analysis of aggregates in heat-induced BSA gels. Food Hydrocolloids 1998, 12, 29-36.
97. Li, C., Mezzenga, R., functionalization of multiwalled carbon nanotubes and their pH-responsive hydrogels with amyloid fibrils. Langmuir 2012, 28, 10142-10146.
98. Wu, H., Morbidelli, M., A model relating structure of colloidal gels to their elastic properties. Langmuir 2001, 17, 1030-1036.
99. Piazza, R., Interactions and phase transitions in protein solutions. Curr. Opin. Colloid Interface Sci. 2000, 5, 38-43.
100. Kim, N., Remmele, R. L. Jr., Liu, D., Razinkov, V. I. et al., Aggregation of anti-streptavidin immunoglobulin gamma-1 involves Fab unfolding and competing growth pathways mediated by pH and salt concentration. Biophys. Chem. 2013, 172, 26-36.
101. Sahin, E., Weiss, W. F., Kroetsch, A. M., King, K. R. et al., Aggregation and pH-temperature phase behavior for aggregates of an IgG2 antibody. J. Pharm. Sci. 2012, 101, 1678-1687.
102. Lewus, R. A., Darcy, P. A., Lenhoff, A. M., Sandler, S. I., Interactions and phase behavior of a monoclonal antibody. Biotechnol. Prog. 2011, 27, 280-289.
103. Anderson, V. J., Lekkerkerker, H. N. W., Insights into phase transition kinetics from colloid science. Nature 2002, 416, 811-815.
104. Bianchi, E., Blaak, R., Likos, C. N., Patchy colloids: state of the art and perspectives. Phys. Chem. Chem. Phys. 2011, 13, 6397-6410.